To receive daily emails from Breaking Christian News to your inbox CLICK HERE

"Now that we know that we can target the basic molecular defects in Alzheimer's disease, we can hope for treatments far better—and more specific—than anything we have today." -Dr. Gerald Weissmann

A new ray of hope has broken through the clouded outcomes associated with Alzheimer's disease. A new research report published in January 2013 print issue of the FASEB Journal (Federation of the American Societies for Experimental Biology) by scientists from the National Institutes of Health shows that when a molecule called TFP5 is injected into mice with disease that is the equivalent of human Alzheimer's, symptoms are reversed and memory is restored—without obvious toxic side effects.

"We hope that clinical trial studies in AD patients should yield an extended and a better quality of life as observed in mice upon TFP5 treatment," said Harish C. Pant, Ph.D., a senior researcher involved in the work from the Laboratory of Neurochemistry at the National Institute of Neurological Disorders at Stroke at the National Institutes of Health in Bethesda, MD. "Therefore, we suggest that TFP5 should be an effective therapeutic compound." (Photo by: Cécile Graat)

To make this discovery, Pant and colleagues used mice with a disease considered the equivalent of Alzheimer's. One set of these mice were injected with the small molecule TFP5, while the other was injected with saline as placebo. The mice, after a series of intraperitoneal injections of TFP5, displayed a substantial reduction in the various disease symptoms along with restoration of memory loss. In addition, the mice receiving TFP5 injections experienced no weight loss, neurological stress (anxiety) or signs of toxicity. The disease in the placebo mice, however, progressed normally as expected. TFP5 was derived from the regulator of a key brain enzyme, called Cdk5. The over activation of Cdk5 is implicated in the formation of plaques and tangles, the major hallmark of Alzheimer's disease.

"The next step is to find out if this molecule can have the same effects in people, and if not, to find out which molecule will," said Gerald Weissmann, M.D., Editor-in-Chief of the FASEB Journal. "Now that we know that we can target the basic molecular defects in Alzheimer's disease, we can hope for treatments far better—and more specific—than anything we have today."

To receive daily emails from Breaking Christian News to your inbox CLICK HERE

Veterans Day is Wednesday. Here's Everyplace Offering Freebies, Discounts to Our Vets

Ancient Evidence Suggests Roman Emperor Sought to Recognize Jesus as God

Charlie Kirk's Family 'Deeply' Disappointed by Tyler Robinson's Trial Delay

Texas Democrats Launch MASSIVE Assault on Second Amendment Just Days after Election Sweep

Gaza-Born DSAer Ahmed Moor Challenges Sen. John Fetterman in PA; Advises Hamas and Palestinian Islamic Jihad Charity, Praised the Oct. 7 Slaughter in Israel

President Trump Chooses Stephen Miller as White House Chief of Staff

SCOTUS: Border Wall Construction Can Resume, Saving Government a Half-Million Dollars a Day

Secretary Hegseth: Impeachment Charges a Stunt 'Driven by Ego and Resentment'

NBC Drops 'National Anthem' from Football Broadcast

Nvidia CEO Jensen Huang Apologizes as Firm Probes Affair with Alleged Chinese Spy

Prayer Alert: Hackers Target America's Freezers; A Threat to Food and Medicine

After the Midterms, What's Next? History Tells Us

'Missing' Memory Card Flips Georgia House Race for GOP

US Supreme Court Likely to Rule in Favor of Catholic Preschool in Religious Liberty Case, Experts Say

Gratitude Changes Your Brain. Here's How

Allie Beth Stuckey Launches a New Space for Christian Women and Moms

2 in 3 Churchgoers Fail Bible Literacy Quiz

This Hail Mary Move Could Save the Supreme Court from the Democrats

Another Florida WIN: CAIR-Florida Shutters Operations as Judge Leaves Terror Designation Intact

Modern-Day Sodom and Gomorrah: California City Moves to Legally Recognize Polyamorous Partnerships

Steve Shultz, Managing Editor
Founder and Owner

Aimee Herd, Editor